Oct 07, 2022 15:00 JST
Source: Olympus
|
|
Olympus EU-ME3 Ultrasound Processor, Delivers Higher Resolution Images for Endoscopic Ultrasound
~ Supporting More Accurate Diagnosis and Treatment of Pancreaticobiliary and Lung Disease ~
- EU-ME3 at United European Gastroenterology Week (UEG Week 2022) October 8 to 11 -
TOKYO / HAMBURG, Oct 07, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, today announced the launch of EU-ME3, a new Endoscopic Ultrasound Processor*, which addresses the needs of healthcare professionals for high-quality clear images when conducting the endoscopic ultrasound procedure. EU-ME3 will be launched in Europe, the Middle East, Africa, parts of Asia, and Oceania within this fiscal year.
| Olympus announces the global launch of the EVIS EUS / EU-ME3 Endoscopic Ultrasound Center. [Image: Olympus Corp] |
Olympus, a pioneer in endoscopic ultrasound (EUS) technology, aims to leverage its expertise to enhance the care pathway in gastrointestinal and respiratory disease management. The technology is used for endoscopic ultrasonography, imaging to support the diagnosis of lesions in the pancreas, the bile ducts, or lesions that are located deep inside the body and are not visible with gastrointestinal endoscopes. In addition, it enables the detailed examination of pancreatitis, pancreatic cancer, and the diagnosis of cancer invasion in the stomach and the esophagus. Endoscopic ultrasound also plays a key role in facilitating the visualization of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for early, minimally invasive diagnosis and lung cancer staging.
"It is said that pancreatic cancer is difficult to be detected in its early stages, and that lung cancer has the highest mortality rate among all cancers. With the launch of the EU-ME3, Olympus aims to enhance the standard of care including these diseases and to further improve the quality of life of patients," said Hironobu Kawano, Head of Endoscopic Solutions Division at Olympus.
- Advancing the dimensions of endosonography
With the needs of healthcare professionals and patient outcomes at its core, EU-ME3 is tailored to improve a variety of procedures.
- Enhanced visualization and usability
EU-ME3 provides outstanding image quality and functionality. The image quality has been substantially enhanced compared to the prior generation model (EU-ME2), providing enhanced visualization, therefore supporting a more reliable diagnosis and treatment.
Shear Wave Quantification, a newly equipped feature for EU-ME3, also contributes to accurate diagnosis by providing quantitative information on the stiffness of tumor and inflamed lesions, which is an important factor when diagnosing the degree of pancreatitis and malignancy of pancreatic cancer during endoscopic ultrasonography.
- Focus on procedure, with tailored technology
The Endoscopic ultrasound procedure typically utilizes a variety of observation modes dependent on procedure type or clinical area. Subsequently, in addition to the basic observation mode, EU-ME3 offers multiple software options for individual clinical needs, aiming to stay flexible in the selection of functions and tailor EU-ME3 depending on specialty.
Smart and customizable user settings make it easy to fulfil needs for multiple specialties and personal requirements. The backlit keyboard includes a simple, easy-to-use large touch panel and trackpad, designed to support better operability and easier cleaning.
With EU-ME3, the aim is to provide seamless workflow integration for healthcare professionals while advancing the dimensions of Endosonography for better overall patient outcome.
About Olympus
In its Endoscopic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. Starting with the world's first gastrocamera in 1950, Olympus' Endoscopic Solutions portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, digital and integrated customer solutions, as well as solutions for infection prevention. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.
Media Contacts Nao Tsukamoto - Global-Public_Relations@olympus.com Jessica Lee - Jessica.yy.lee@fleishman.com
* Registered name: EVIS EUS ENDOSCOPIC ULTRASOUND CENTER OLYMPUS EU-ME3. EU-ME3 is manufactured by Olympus Medical Systems Corporation. * Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.
Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLY] https://www.olympus-global.com
Source: Olympus Sectors: BioTech, Healthcare & Pharm, MedTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|
Latest Release
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam Dec 26, 2024 12:00 JST
| Mazda Production and Sales Results for November 2024 Dec 26, 2024 11:46 JST
| MHI Conducts Nighttime and Long-Distance Highway Demonstration Testing of Unmanned Aerial Vehicle Currently Under Development Dec 26, 2024 09:47 JST
| Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam Dec 24, 2024 13:19 JST
| Nissan and Honda sign MOU to consider business integration Dec 24, 2024 11:18 JST
| Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year Dec 24, 2024 11:00 JST
| Nissan, Honda, and Mitsubishi Motors sign MOU on collaborative considerations Dec 24, 2024 10:54 JST
| GAC Honda Begins Operation of New Energy Vehicle (NEV) Production Factory in Guangzhou, China Dec 24, 2024 10:23 JST
| Sarawak Premier Makes Inaugural Visit to Mitsubishi Power's Takasago Hydrogen Park Dec 24, 2024 10:10 JST
| Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases Dec 23, 2024 17:22 JST
| Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration Dec 23, 2024 13:30 JST
| Mitsubishi Motors Cumulative Production Reaches One Million Units in Indonesia Dec 20, 2024 17:35 JST
| Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Washington Dulles International Airport Dec 20, 2024 17:24 JST
| Toyota Launches Alphard and Vellfire PHEV Models in Japan Dec 20, 2024 15:38 JST
| 6G Begins! Embarking on a New Journey of Global Interoperable Standards Dec 19, 2024 16:50 JST
| MI LNG Company to Change Corporate Name to MILES Dec 19, 2024 13:49 JST
| Two Honda 0 Series Prototype Models to Premiere at CES 2025 Dec 19, 2024 12:30 JST
| Honda Presents World Premiere of Honda S+ Shift, Next-generation e:HEV Technology Dec 19, 2024 12:13 JST
| NEC Completes new Asia Pacific submarine cable Dec 19, 2024 12:02 JST
| Enablement of JCB Contactless Payment at All NJ TRANSIT Contactless Bus and Light Rail Validators in New Jersey, New York, and Pennsylvania Dec 19, 2024 12:00 JST
|
More Latest Release >>
|